Cardiff Lexington Corporation: Cardiff Lexington Announces Second Quarter 2026 Financial Results
Cardiff Lexington Corporation (OTCQX:CDIX) filed its Form 10-Q for the quarter ended June 30, 2026. The company reported Q2 2026 revenue of $2.16M versus $2.79M in 2025, and a net loss of $2.48M. For six months, revenue fell to $4.38M and net loss was $5.57M. It cited working capital constraints and plans to evaluate debt restructuring and equity infusions.
How this was made
The 30-second read
Why it matters
The 10-Q filing provides fresh financial datapoints and management commentary on liquidity constraints, including potential debt restructuring and equity infusions at high cost of capital.
Market read
Fresh quarterly filing and disclosed losses shift attention to financing risk and execution, with an investor call scheduled the same day.
What to watch
The article emphasizes implicit realization rate and working capital constraints but does not quantify the magnitude of the financing plan; traders should watch the 10-Q details for debt terms, covenant risk, and any dilution expectations.
Background
Cardiff Lexington is an OTC healthcare services holding company building orthopedic, spine, and pain-management platforms under Nova Ortho and Spine.
Ticker impact
Cardiff Lexington filed its June 30, 2026 Form 10-Q and reported Q2 revenue of $2.16M with a net loss of $2.48M.
Likely negative-to-neutral near term, with volatility driven by any follow-on details on working capital, debt restructuring, or equity infusions.
The article discloses weaker year-to-date revenue, a lower implicit realization rate, and a small adjusted EBITDA loss, while explicitly stating working capital constraints and evaluation of costly capital actions.
Market effects
Reinforces funding and reimbursement-realization sensitivity for orthopedic and pain-management provider networks.
Focus on Florida and Georgia expansion may attract local attention but does not change broader regional fundamentals.
Limited, as the disclosure is company-specific and OTC-listed.
Counterpoint
Despite revenue decline, gross profit was strong (57% in the first half) and the company is still adding locations and clinical teams, suggesting operating leverage could improve if working capital eases.
Key entities
- companyCardiff Lexington Corporation
OTC healthcare services holding company focused on orthopedic, spine, and pain management platforms.
- businessNova Ortho and Spine
Operating network referenced as the company’s growth platform; management opened a 12th location in Tallahassee.
- regulatory_filingSEC Form 10-Q
Quarterly report filed for the quarter ended June 30, 2026, containing the disclosed financial results.
